

Supplementary Material Table 1: Location of gene promoters and regions that were amplified and the CpG dinucleotide positions within the regions where DNA methylation was quantified.

Gene	Chromosome	Promoter		Amplicon		CpGs
		<i>Start</i>	<i>End</i>	<i>Start</i>	<i>End</i>	
P16	9	21964701	21965538	21965321	21965395	21965350 (position 1) 21965355 (position 2) 21965357 (position 3) 21965361 (position 4) 21965365 (position 5) 21965368 (position 6) 21965374 (position 7)
P53	17	7531143	7531743	7531409	7531628	7531486 (position 1) 7531473 (position 2) 7531469 (position 3) 7531458 (position 4)

Supplementary Material Table 2: Primers used for DNA methylation analysis

ID	Forward Primer (5' to 3')	Reverse Primer (5' to 3')	Sequencing Primer (5' to 3')	Sequence analyzed ^a
Global methylation analysis				
<i>Alu</i>	Biotin- TTTTTATTAATAA ATAATAAATT	CCCAAATAAAATACAAT AA	AATAACTAAAATTACAAAC	<u>G</u> / <u>AC</u> / <u>TG</u> / <u>AC</u> / <u>TG</u> / <u>ACCACCA</u>
<i>LINE-1</i>	TTTTGAGTTAGGTG TGGGATATA	Biotin- AAAATCAAAAATCCCTT TC	AGTTAGGTGTGGGATATAGT	<u>TTC</u> / <u>TGTGGTGC</u> / <u>TGTC</u> / <u>TG</u>
Gene-specific methylation analysis				
<i>p16</i>	AGGGGTTGTTGG TTATTAG	Biotin - CTACCTACTCTCCCCCTCT C	GGTTGGTTATTAGAGGGT	<u>GGGGC</u> / <u>TGGATC</u> / <u>TGC</u> / <u>TGTGC</u> / <u>TGTT</u> / <u>TGGC</u> <u>/TGGTTGC</u> / <u>TG</u>
<i>p53</i>	Biotin - TTAGGAGTTTATTT AATTTAGGGAAG	TATCCAACCTTATACCA AAAACCTC	TCCAAAAACAAATAACTAC TAAACTC	<u>CG</u> / <u>AAAAACACTTTACG</u> / <u>ATT</u> <u>CG</u> / <u>AAACT</u> <u>AAAAACG</u> / <u>AT</u> <u>ACTTT</u>

^aNucleotides at which DNA methylation was measured are underlined

Supplementary Material Table 3. Estimates and 95% confidence intervals from general linear regression models that compared DNA methylation (%mC) in umbilical cord blood and maternal blood according to tertiles of total urinary arsenic ($\mu\text{g/L}$). Models are adjusted for maternal BMI and creatinine. Additionally, cord blood models are adjusted for fetal age.

		Cord Blood			Maternal Blood		
		β	95% CI	p-value	β	95% CI	p-value
LINE-1	High	0.95	-0.09, 1.99	0.07	0.06	-1.17, 1.30	0.92
	Med	0.32	-0.53, 1.17	0.46	0.05	-0.99, 1.10	0.92
	Low	Ref.	-	-	Ref.	-	-
Alu	High	0.14	-0.30, 0.58	0.52	-0.12	-0.54, 0.31	0.59
	Med	0.02	-0.34, 0.38	0.92	0.24	-0.12, 0.60	0.19
	Low	Ref.	-	-	Ref.	-	-
P16 pos 1	High	0.42	-0.37, 1.21	0.29	0.27	-0.64, 1.18	0.55
	Med	0.04	-0.62, 0.69	0.91	-0.01	-0.79, 0.76	0.97
	Low	Ref.	-	-	Ref.	-	-
P16 pos 2	High	0.64	-0.06, 1.35	0.07	0.47	-0.52, 1.46	0.5
	Med	-0.03	-0.62, 0.55	0.91	0.17	-0.67, 1.02	0.74
	Low	Ref.	-	-	Ref.	-	-
P16 pos 3	High	0.22	-0.21, 0.64	0.32	0.27	-0.10, 0.64	0.15
	Med	-0.02	-0.38, 0.33	0.89	-0.02	-0.33, 0.29	0.9
	Low	Ref.	-	-	Ref.	-	-
P16 pos 4	High	0.4	0.13, 0.92	0.14	0.38	-0.22, 0.98	0.98
	Med	-0.09	0.52, 0.35	0.7	0.35	-0.15, 0.86	0.86
	Low	Ref.	-	-	Ref.	-	-
P16 pos 5	High	0.22	-0.27, 0.71	0.38	0.09	-0.33, 0.52	0.66
	Med	-0.23	-0.64, 0.17	0.26	0.13	-0.24, 0.49	0.49
	Low	Ref.	-	-	Ref.	-	-
P16 pos 6	High	0.16	-0.26, 0.58	0.44	0.22	-0.17, 0.62	0.26
	Med	-0.23	-0.58, 0.12	0.2	0.07	-0.26, 0.40	0.67
	Low	Ref.	-	-	Ref.	-	-
P16 pos 7	High	0.37	-0.23, 0.97	0.22	0.55	-0.70, 1.80	0.39
	Med	-0.31	-0.81, 0.19	0.22	0.41	-0.66, 1.48	0.45
	Low	Ref.	-	-	Ref.	-	-
P53 pos 1	High	0.29	-0.24, 0.82	0.28	-0.05	-1.09, 1.00	0.93
	Med	-0.10	-0.55, 0.35	0.66	-0.58	1.52, 0.36	0.22
	Low	Ref.	-	-	Ref.	-	-
P53 pos 2	High	-0.32	-1.96, 1.33	0.7	-0.06	-1.67, 1.56	0.94
	Med	0.39	-1.78, 1.00	0.58	-0.50	-0.95, 0.95	0.5
	Low	Ref.	-	-	Ref.	-	-
P53 pos 3	High	0.19	-0.57, 0.96	0.62	-0.09	-0.70, 0.52	0.77
	Med	0.17	-0.48, 0.82	0.6	-0.11	-0.66, 0.43	0.68
	Low	Ref.	-	-	Ref.	-	-
p53 pos 4	High	-0.27	-1.16, 0.63	0.55	0.27	-0.64, 1.17	0.56
	Med	-0.42	-1.18, 0.33	0.27	0.38	-0.43, 1.19	0.36
	Low	Ref.	-	-	Ref.	-	-